Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Nov;26(11):2877-2901.
doi: 10.1007/s12094-024-03605-2. Epub 2024 Aug 7.

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

Laura Ortega Morán #  1 , Francisco José Pelegrín Mateo #  2 , Rut Porta Balanyà #  3 , Jacobo Rogado Revuelta #  4 , Silverio Ros Martínez #  5 , José Pablo Berros Fombella #  6 , Elena María Brozos Vázquez #  7 , Natalia Luque Caro #  8 , José Muñoz Langa #  9 , Mercedes Salgado Fernández #  10
Affiliations
Practice Guideline

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023)

Laura Ortega Morán et al. Clin Transl Oncol. 2024 Nov.

Abstract

The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.

Keywords: Anticoagulation; Cancer; Direct oral anticoagulants; Guidelines; Low-molecular-weight heparins; Venous thromboembolism.

PubMed Disclaimer

Conflict of interest statement

LOM: speaker at LEO Pharma, Rovi and Menarini. JRR: speaker at LEO Pharma. EMBV: member of the Advisory Board at Pfizer and Bayer; speaker at Rovi and LEO Pharma; travel and accommodation at Sanofi. NLC: speaker at Roche, AstraZeneca, Amgen and Merck. MSF: member of the Advisory Board at Pfizer; speaker at Sanofi, Rovi, LEO Pharma and Techdow. FJPM, RPB, SRM, JPBF and JML: nothing to disclose.

References

    1. Mulder FI, Horváth-Puhó E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137(14):1959–69. - PubMed
    1. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019;3(22):3770–9. - PMC - PubMed
    1. Kakkar AK, Haas S, Wolf H, Encke A. Evaluation of perioperative fatal pulmonary embolism and death in cancer surgical patients: the MC-4 cancer substudy. Thromb Haemost. 2005;94(4):867–71. - PubMed
    1. Falanga A, Schieppati F, Russo L. Pathophysiology 1. Mechanisms of thrombosis in cancer patients. Cancer Treat Res. 2019;179:11–36. - PubMed
    1. Ferroni P, Formica V, Roseli M, Guadagni F. Thromboembolic events in patients treated with anti-angiogenic drugs. Curr Vasc Pharmacol. 2010;8(1):102–13. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources